It’s a disease that has baffled health professionals for years, but our researchers have taken a significant step forward in understanding migraine.
A new study, published in NMR in Biomedicine, reveals higher levels of the chemical gamma-aminobutyric acid in the brain of migraine sufferers, supporting the theory that migraines are linked to a chemical imbalance in the brain.
“The finding paves the way for the discovery of new, effective treatments for migraines,” said lead researcher Maria Aguila, PhD candidate in the Faculty of Health Sciences.
“For such a debilitating condition, very little is known about migraine so this is a big step forward and could lead to better diagnosis and treatment of the disease in the future,” she said.
Gamma-aminobutyric acid or GABA as it is commonly known, is the most abundant inhibitory brain chemical and has long been suspected to play a role in migraines due to its ability to influence pain. This study is the first to accurately measure GABA levels in the living brain.
“We still don’t know what causes migraine, how it starts and ends, or why the triggers appear to differ from one person to the next, but this discovery means that we can now be much more specific with our research going forward,” said Ms Aguila.
“For example, GABA could be used to help us identify migraine sufferers and track responses to drug trials, and measuring GABA levels over a period of time could well reveal what’s causing attacks.”
The study compared the levels of GABA in twenty chronic migraine sufferers to an age and gender matched control group who did not experience any form of regular headaches. Brain scans were conducted when the participants were not having a migraine.
The measurement of GABA levels in the brain was made possible by a novel spectroscopy technique associated with MRI developed by researchers at the University of Sydney Brain and Mind Centre.
Associate Professor in Neuroimaging, Jim Lagopoulos said the ability to directly measure these chemicals in the brain would not have been possible several years ago.
“These advances not only allow us to study fundamental changes in brain chemistry that are associated with migraine, but they also open a whole new world with respect to monitoring a patient’s response to treatment and compliance,” he said.
The researchers were unable to tell if the increase in GABA is related to a recent migraine attack or signalling a new one as the scanning process is currently too complex to carry out during a migraine attack.
The study design was conceived by Professor Kathryn Refshauge and executed by researchers from the University of Sydney’s Faculty of Health Sciences and Brain and Mind Centre, Neuroscience Research Australia, University of the Philippines and University of New South Wales.
(Source: The University of Sydney, NMR in Biomedicine)